Kiniksa Pharmaceuticals International, plc
KNSA$1.11B
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaLONDON315 employees
Drugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Aug 4, 2026
6wMarket Overview
Stock performance and key metrics
KNSA News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
KPL-387
Pericarditis
mavrilimumab
COVID
Rilonacept
Recurrent Pericarditis
prednisone
Giant Cell Arteritis
KPL-404
Arthritis, Rheumatoid
KPL-914
Recurrent Pericarditis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KPL-387 | Phase 3 | Pericarditis | - | - |
mavrilimumab | Phase 3 | COVID | - | - |
Rilonacept | Phase 3 | Recurrent Pericarditis | - | - |
prednisone | Phase 2 | Giant Cell Arteritis | - | - |
KPL-404 | Phase 2 | Arthritis, Rheumatoid | - | - |
KPL-914 | Phase 2 | Recurrent Pericarditis | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply